1. A buffered composition comprising a first monovalent VLP derived from a first Norovirus genogroup and a second monovalent
VLP derived from a second Norovirus genogroup, wherein the first Norovirus genogroup is genogroup I and the second Norovirus
genogroup is genogroup II, wherein said buffer is selected from L-histidine and imidazole, and wherein the composition is
formulated as a liquid.